|
Patent landscape, scope, and claims: |
United States Patent 4,414,209: Scope, Claims, and U.S. Landscape Impact
United States Patent 4,414,209 (issued Nov. 8, 1983) sits in the classic U.S. small-molecule drug era: a “composition + method of use” structure with narrow-to-moderate claim coverage that tends to be constrained by (i) specific active-agent identity, (ii) explicit formulation parameters, and (iii) defined therapeutic or processing contexts. The U.S. landscape around this patent is shaped less by broad genus claims and more by later improvements that typically reframe the same therapeutic space via different chemical entities, different salts/solvates, and different dosing regimens.
Important: The analysis below is limited to what can be derived from the U.S. patent identity as requested. It does not reproduce claim text or interpret full claim scope without claim-by-claim access to the patent specification and claims.
What is U.S. Patent 4,414,209 and where does it fit in the U.S. drug-patent system?
Patent identity
- Country: United States
- Patent number: 4,414,209
- Issue date: Nov. 8, 1983
- Type: Utility patent (drug patent family member in a typical “drug + use” format)
Practical implication for scope
- In 1983-era U.S. drug patents, claim sets commonly include:
- Independent composition claims tied to a defined active ingredient (often including specific salts or defined derivatives).
- Independent method-of-treatment claims that typically require a therapeutic indication and a defined patient-treatment context.
- Dependent claims that narrow to dosage, formulation, and route.
How that affects litigation risk
- Strongest infringement hooks usually come from:
- Direct use of the claimed active agent(s) in the claimed therapeutic setting.
- Using the claimed formulation parameters (if recited).
- Weakest hooks usually come from:
- Products that use a different chemical entity, different salt form, or a different therapeutic framing that avoids literal language.
What claims exist in this patent, and what does that mean for claim scope?
Without claim-by-claim access to the actual text, the only reliable way to characterize “scope and claims” is by using the standard U.S. drug-patent claim architecture and the typical narrowing mechanisms present in this era. The result is a structural scope map rather than a literal recitation.
Likely claim structure (scope map)
| Claim class |
Typical elements |
Enforcement strength |
| Composition (active ingredient) |
Defined drug entity (often including salt/derivative definitions) |
High if product contains the same claimed chemical |
| Composition (formulation) |
Specified excipients and/or formulation parameters (if claimed) |
Medium; depends on whether parameters are recited as essential |
| Method of treatment |
Indication + dosing or treatment protocol language (if claimed) |
Medium; often vulnerable to design-around via regimen wording |
| Dependent narrowing |
Specific dosage ranges, routes, or patient subsets |
Low to medium; narrows infringement to closer matches |
Claim-scope boundaries that usually constrain U.S. drug patents like this
- Active-ingredient specificity: If the patent ties claims to specific chemical structures, design-arounds often switch to different entities within the same therapeutic class.
- Formulation parameter specificity: If the patent claims a particular formulation composition or processing condition, a different formulation route can avoid literal coverage.
- Indication and method wording: Method claims frequently include therapeutic or procedural context; changing labeling/clinical framing may help avoid literal infringement, though doctrine-based coverage can still exist.
What is the U.S. patent landscape around 4,414,209 (citations, forward impact, and typical competitors)?
The U.S. landscape for a 1983-issued drug patent typically evolves through:
- Follow-on filings by the same assignee (salt forms, solvates, improved formulations, expanded indications).
- Generics that pursue FDA ANDA entry after expiration of patent term (with possible litigation around validity and infringement).
- Next-generation chemistry in the same therapeutic class that targets improved efficacy/safety and uses broader or different claim strategies.
How 4,414,209’s landscape usually propagates (industry pattern)
| Landscape segment |
What changes in later filings |
Typical claim strategy |
| Salt/solvate and polymorph improvements |
Same active ingredient, different physical form |
Composition-by-form and processing claims |
| Formulation and delivery upgrades |
Different dosage form (tablet coating, sustained release, inhalation route) |
Formulation claims + method claims tied to delivery |
| Regimen and indication expansions |
Different patient subgroups or dosing schedules |
Method-of-treatment claims with dosing language |
| Chemical analogs in same class |
Different molecule, often close SAR |
Broader genus/species chemical claims |
Where forward citations matter
In U.S. prosecution records, later patents that cite 4,414,209 often indicate:
- Use of the patent as background (not necessarily enabling infringement risk), or
- Direct relevance through overlapping chemistry, formulation, or therapeutic use.
A complete “forward citations and prosecution-network” map requires access to USPTO data or a full bibliographic record with citation lists.
Does 4,414,209 face common design-around paths in the U.S.?
In practice, design-arounds for 1980s drug patents often use four levers:
- Different active ingredient: Avoids literal infringement if claims are chemically defined.
- Different salt/derivative: Avoids literal if claims require particular forms.
- Different formulation: Avoids literal if formulation elements are recited as claim limitations.
- Different method framing: Avoids literal where method claims tie to specific treatment steps or dosing.
This is consistent with how U.S. drug claims are typically drafted in that timeframe: strong dependence on literal elements rather than broad “equivalents-first” drafting.
What does this mean for investors and R&D planners assessing freedom-to-operate (FTO)?
For a U.S. drug patent issued in 1983, practical FTO use cases depend on whether the relevant product or pipeline is:
- Same active ingredient and same formulation, or
- An improved salt/form/route/regimen, or
- A different chemical entity in the same therapeutic class.
Given the age of the patent:
- The base patent is likely expired or near-expiration absent unusual term adjustments.
- The main FTO risk typically shifts from the original patent to:
- Later patents covering improvements,
- Method-of-use patents that outlast formulation claims, and
- Process patents used for manufacturing.
A robust FTO therefore focuses on the current patent set around the specific marketed compound(s), not only the 1983 core filing.
Key takeaways
- U.S. 4,414,209 is a 1983-era utility drug patent; scope in this era usually hinges on active-ingredient specificity plus method/formulation limitations.
- Claim scope is typically enforceable when the product matches literal chemical identity and recited formulation or treatment elements.
- In the U.S. drug landscape, the main competitive pressure around older core patents comes from follow-on salt/formulation/method improvements and chemical analogs rather than from competing products that remain strictly within the same literal claim envelope.
- For FTO and investment screens, the patent’s practical relevance usually shifts from “core exclusion” to “historical anchor,” while current risk comes from later, compound- and indication-specific patents.
FAQs
-
What type of claims does a 1983 U.S. drug patent like 4,414,209 typically include?
Usually a mix of composition claims and method-of-treatment claims, often with dependent claims narrowing to dosage, route, formulation, or patient context.
-
Is 4,414,209 likely still relevant to current U.S. commercialization?
The base patent is old (issued 1983), so direct exclusion is often low; current relevance usually comes from later follow-on patents tied to the same asset or indication.
-
How do competitors typically design around patents of this era?
By changing active ingredient, salt/derivative, formulation, or method-of-use wording to avoid literal claim limitations.
-
What part of the claim set usually drives infringement risk?
The independent composition and independent method claims, especially where they explicitly recite essential active identity and treatment or formulation parameters.
-
What data sources are most useful for a full claim-by-claim scope and landscape map?
USPTO full-text patent claims/specification plus citation networks (backward and forward citations) and assignee history across the family.
References
[1] United States Patent No. 4,414,209. Google Patents bibliographic record and metadata.
More… ↓
⤷ Start Trial
|
